Article
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
European journal of pharmacology - 30 Sept 2011
Tandon Ruchi, Kapoor Shweta, Vali Shireen, Senthil V, Nithya D, Venkataramanan R, Sharma Ashish, Talwadkar Anay, Ray Abhijit, Bhatnagar Pradip K, Dastidar Sunanda G
Abstract excerpt
Small molecule inhibitors of epidermal growth factor receptors (EGFR) have been found to show a good initial response in cancer patients but during the course of treatment, patients develop resistance after a few weeks of time. Development of secondary mutations or over-activation of insulin like growth factor (IGF-1R) pathway are a few of the several mechanisms proposed to explain the resistance. To study the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.